Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Colorectal Neoplasms 55Neoplasms 31Unspecified Adult Solid Tumor, Protocol Specific 30Pancreatic Neoplasms 28Neoplasm Metastasis 24Colonic Neoplasms 23Stomach Neoplasms 22Rectal Neoplasms 20Neuroblastoma 15Lung Neoplasms 13Esophageal Neoplasms 12Glioblastoma 11Central Nervous System Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Brain Neoplasms 11Astrocytoma 11Small Cell Lung Carcinoma 9Glioma 9Oligodendroglioma 8Gliosarcoma 8Breast Neoplasms 8Esophageal Squamous Cell Carcinoma 7Adenocarcinoma 7Unspecified Childhood Solid Tumor, Protocol Specific 6Ovarian Neoplasms 6Gallbladder Neoplasms 6Carcinoma, Hepatocellular 6Bile Duct Neoplasms 6Triple Negative Breast Neoplasms 5Solid Tumor 5

Interventions

Irinotecan 2Injections 2vistusertib 1urelumab 1sapanisertib 1durvalumab 1danvatirsen 1ceralasertib 1cediranib 1atezolizumab 1ZD4054 1Topotecan 1Tiragolumab 1Rosuvastatin Calcium 1Radiotherapy 1Rabeprazole 1Metformin 1HM781-36B 1Furosemide 1Digoxin 1ATP Binding Cassette Transporter, Subfamily B, Member 1 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 13-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Malignancies × Irinotecan × Clear all
NCT00986843 2013-04-05

Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102)

Hanmi Pharmaceutical Company Limited

Phase 1 Completed
14 enrolled

Advanced Solid Malignancies

NCT00979563 2011-12-07

Oratecan-101

Hanmi Pharmaceutical Company Limited

Phase 1 Completed
15 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡